Item 7.01. Regulation FD Disclosure.
On
The information contained in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On
The Company has previously disclosed that it is commencing the close out of its
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements, including
statements regarding sales of RAPIVAB and expectations regarding the Company's
galidesivir program. These statements involve known and unknown risks,
uncertainties, and other factors which may cause actual results to be materially
different from those expressed or implied by the forward-looking statements.
These statements reflect our current views with respect to future events and are
based on assumptions and are subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements. Some of the factors that could affect the forward-looking
statements contained herein include: the Company relies on third-party
manufacturers to manufacture RAPIVAB in a timely manner and in accordance with
applicable governmental regulations, and any failure of such third-party
manufacturers to perform their obligations could impact the Company's ability to
supply RAPIVAB pursuant to its government procurement contract; the availability
of government funding; government contracts contain certain terms and conditions
that subject the Company to additional risks; and the ongoing COVID-19 pandemic,
which could create challenges in all aspects of the Company's business,
including without limitation delays, stoppages, difficulties, and increased
expenses with respect to the Company's and its partners' supply chains,
negatively impact the Company's ability to access the capital or credit markets
to finance its operations, or have the effect of heightening the other risks
described herein or in the documents the Company files periodically with the
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description Amendment, datedAugust 10, 2022 , to the Contract dated 10.1September 1, 2018 betweenBioCryst Pharmaceuticals, Inc. and theDepartment of Health and Human Services Press release datedAugust 25, 2022 entitled "U.S. Government 99.1 Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source